AAA
LXEO icon

Affinity Asset Advisors’s Lexeo Therapeutics LXEO Stock Holding History

Affinity Asset Advisors’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$29M Buy
5,050,211
+1,850,211
+58% +$13.1M 1.5% 20
2025
Q4 		$31.8M Sell
3,200,000
-670,527
-17% -$6.12M 1.81% 18
2025
Q3 		$25.7M Buy
3,870,527
+281,172
+8% +$1.36M 2.24% 16
2025
Q2 		$14.4M Buy
3,589,355
+2,108,474
+142% +$6.93M 1.97% 13
2025
Q1 		$5.14M Buy
+1,480,881
New +$6.56M 0.49% 41

Other funds holding LXEO

PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Affinity Asset Advisors's LXEO Position: Q1 2026 in Review

Affinity Asset Advisors increased its Lexeo Therapeutics (LXEO) stake by 58% in Q1 2026, buying an estimated $13.1M and bringing the position to 5,050,211 shares worth $29M. The position accounts for 1.5% of the portfolio, ranked #20.

Affinity Asset Advisors first reported a position in LXEO in Q1 2025 and has held it in 5 quarters since. The position peaked at $31.8M in Q4 2025. 139 funds tracked by Wall St. Rank hold LXEO as of Q1 2026.

  • Affinity Asset Advisors held 5,050,211 shares of Lexeo Therapeutics worth $29M as of Q1 2026.
  • Affinity Asset Advisors bought 1,850,211 Lexeo Therapeutics shares in Q1 2026, an estimated $13.1M.
  • Lexeo Therapeutics made up 1.5% of Affinity Asset Advisors's portfolio in Q1 2026, its #20 holding.
  • Affinity Asset Advisors first reported a position in Lexeo Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • Affinity Asset Advisors's Lexeo Therapeutics position peaked at $31.8M in Q4 2025.
  • 139 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q1 2026.

Based on Affinity Asset Advisors's 13F filing for Q1 2026, filed 14 May 2026.